Question explored with the scientific record
Does anastrazole have antiparasitic properties being it is an -anole medication
The short version: the evidence you provided does not test anastrozole against any parasite, so there is no basis to claim it has antiparasitic properties.
The hypothesis that anastrozole might work against parasites because it is an "-anole" drug is a guess about drug class, not a finding. The "-anole" suffix refers to the triazole ring in the molecule, which is the part that binds to the aromatase enzyme. The evidence you gave covers anastrozole's effects on human estrogen synthesis, lipid metabolism, and breast cancer outcomes [1, 2, 5, 7, 10]. None of the 15 records test anastrozole against a single parasite species, in vitro or in vivo. The closest is a study of clotrimazole, a different triazole antifungal, in zebrafish [11], but that is a different drug in a different context.
Some triazole drugs do have antiparasitic activity, but that is a property of the specific molecule, not the ring. Fluconazole, itraconazole, and posaconazole are triazoles that work against fungal and some protozoan infections because they inhibit a fungal cytochrome P450 enzyme (lanosterol 14α-demethylase) that human aromatase inhibitors do not target at relevant concentrations. Anastrozole was designed to be highly selective for human aromatase, with a Ki of about 1.5 to 1.8 nM [3, 6], and it shows no meaningful binding to other cytochrome P450 enzymes at therapeutic levels [6]. That selectivity is the opposite of what you would want for an antiparasitic drug.
My call: there is no evidence anastrozole has antiparasitic properties, and the mechanism of action makes it unlikely. Confidence: high.
Sources used 8
-
Effect of anastrozole and tamoxifen on lipid metabolism in Japanese postmenopausal women with early breast cancer
In a randomized trial of 49 Japanese postmenopausal women with early breast cancer, anastrozole versus tamoxifen produced distinct lipid metabolism effects over 12 weeks, with anastrozole preserving cholesterol levels but improving HDL-C, triglycerides, and remnant lipoprotein c…
DOI: 10.1080/02841860510007585 -
The effect of third-generation aromatase inhibitors on aromatase avtivity in visceral adipose tissue
Visceral adipose tissue aromatase activity decreases and serum adiponectin increases when Syrian hamsters with diet-induced metabolic syndrome are treated with third-generation aromatase inhibitors, with letrozole producing the strongest effects.
DOI: 10.15421/021831 -
Dual aromatase–sulfatase inhibitors based on the anastrozole template: synthesis, in vitro SAR, molecular modelling and in vivo activity
This study presents the synthesis and biological evaluation of novel Dual Aromatase-Sulfatase Inhibitors (DASIs) based on the Anastrozole template, demonstrating potent in vitro and in vivo activity against aromatase and steroid sulfatase, with implications for hormone-dependent…
DOI: 10.1039/b707768h -
Functional Genetic Polymorphisms in the Aromatase Gene CYP19 Vary the Response of Breast Cancer Patients to Neoadjuvant Therapy with Aromatase Inhibitors
This study shows that two common CYP19 promoter polymorphisms (rs6493497 and rs7176005) near exon 1.1 alter aromatase expression/activity and plasma estrogen levels, shaping breast cancer patients' responses to neoadjuvant aromatase inhibitors, with functional genomics supportin…
DOI: 10.1158/0008-5472.can-09-3224 -
Pharmacological profile of MEN 11066, a novel potent and selective aromatase inhibitor
This study characterizes MEN 11066 as a highly potent and selective non-steroidal aromatase inhibitor with strong in vitro and in vivo activity against aromatase, comparable to letrozole and analogous to anastrozole, while showing high selectivity with minimal off-target effects…
DOI: 10.1016/s0960-0760(03)00073-6 -
New findings about endocrine therapy for breast cancer
A comprehensive 2003 review of emerging adjuvant endocrine therapy data for breast cancer, highlighting the roles of ovarian suppression and aromatase inhibitors (letrozole, anastrozole) versus tamoxifen across premenopausal and postmenopausal settings, with implications for pra…
DOI: 10.1016/s0960-9776(03)00138-3 -
An integrated view of aromatase and its inhibition
This 2003 review integrates clinical and mechanistic data on aromatase inhibitors in postmenopausal breast cancer, highlighting that estrogen receptor status is the primary predictor of response but that additional biomarkers (PgR, c-erbB2, in situ aromatase activity, and gene-e…
DOI: 10.1016/s0960-0760(03)00352-2 -
Climate change and pollution speed declines in zebrafish populations
The study shows that elevated temperature together with exposure to the aromatase-inhibiting chemical clotrimazole and inbreeding interact additively to skew zebrafish population sex ratios toward males, reduce reproduction and population viability—effects strongest in inbred li…
DOI: 10.1073/pnas.1416269112